AcelRx Pharmaceuticals (NASDAQ:ACRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRXGet Rating) in a research note issued to investors on Thursday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Other analysts have also recently issued reports about the company. Zacks Investment Research cut AcelRx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, March 15th. HC Wainwright downgraded AcelRx Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday, March 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of AcelRx Pharmaceuticals in a research report on Friday, March 11th.

ACRX opened at $0.22 on Thursday. The stock has a 50-day moving average price of $0.31 and a 200-day moving average price of $0.50. The firm has a market cap of $32.98 million, a PE ratio of -0.77 and a beta of 0.70. AcelRx Pharmaceuticals has a 1 year low of $0.22 and a 1 year high of $1.67.

AcelRx Pharmaceuticals (NASDAQ:ACRXGet Rating) last released its quarterly earnings results on Thursday, March 10th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.06). During the same period in the prior year, the company earned ($0.10) EPS. As a group, equities analysts anticipate that AcelRx Pharmaceuticals will post -0.22 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of ACRX. Values First Advisors Inc. boosted its stake in shares of AcelRx Pharmaceuticals by 23.7% in the first quarter. Values First Advisors Inc. now owns 642,515 shares of the specialty pharmaceutical company’s stock worth $183,000 after acquiring an additional 123,241 shares during the last quarter. apricus wealth LLC purchased a new position in AcelRx Pharmaceuticals during the fourth quarter worth approximately $73,000. Millennium Management LLC lifted its position in AcelRx Pharmaceuticals by 40.1% during the fourth quarter. Millennium Management LLC now owns 334,248 shares of the specialty pharmaceutical company’s stock worth $187,000 after buying an additional 95,716 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its position in AcelRx Pharmaceuticals by 12.3% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 3,721,586 shares of the specialty pharmaceutical company’s stock worth $2,085,000 after buying an additional 407,507 shares in the last quarter. Finally, Cornerstone Capital Inc. purchased a new position in AcelRx Pharmaceuticals during the fourth quarter worth approximately $45,000. 23.12% of the stock is currently owned by institutional investors.

AcelRx Pharmaceuticals Company Profile (Get Rating)

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures.

Read More

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.